Changes in immunologic variables (TNF-a, sCD8 and sCD4) during danazol treatment in patients with endometriosis

International Journal of Fertility and Women's Medicine

Volumn 42, Issue 3, 1997, Pages 211-214

  Matalliotakis, I ^a,b   Neonaki, M ^a   Zolindaki, A ^a   Hassan, E ^a   Georgoulias, V ^a   Koumantakis, E ^a  

^a UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

^b NONE   (Greece)

Author keywords

Danazol; Endometriosis; SCD4; SCD8; TNF a (tumor necrosis factor)

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DANAZOL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; ENDOMETRIOSIS; FEMALE; HUMAN; IMMUNOREGULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

ADULT; ANTIGENS, CD4; ANTIGENS, CD8; DANAZOL; ENDOMETRIOSIS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IMMUNITY, CELLULAR; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031431774     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Dmowski WP, Gebel HM, Rawlins RG: Immunologic aspects of endometriosis. Obstet Gynecol Clin North Am 16:93-102, 1989.
2. Braun DP, Muriana A, Gebel H, et al: Monocytemediated enhancement of endometrial cell proliferation in women with endometriosis. Fertil Steril 61:78-84, 1994.
3. Badawy SZ, Guenca V, Stitzel A, et al: Autoimmune phenomena in infertile patients with endometriosis. Obstet Gynecol 63:271-277, 1984.
4. Haney AF: Endometriosis-associated infertility. Bail Clinic Obstet Gynaecol 74:791-812, 1993.
5. Koumantakis E, Matalliotakis I, Neonaki M, et al: Soluble serum interleukin-2 receptor, interleukin-6 and interleukin-la in patients with endometriosis and in controls. Arch Gynecol Obstet 255:107-112, 1994.
6. Hill JA: Immunopathology of endometriosis: immunological cytokines in disease development, in Coutinho EM, Spinola P, Mour LH (eds): Progress in the Management of Endometriosis. Parthenon Publishing Group, U.K, 1995.
7. Barbieri RL, Hornistein MD: Medical therapy for endometriosis, in Wilson EA (ed): Endometriosis. New York, Alan R. Liss, pp 111-140, 1987.
8. Koumantakis E, Matalliotakis I, Makrigiannakis A, et al: Danazol suppresses both cell-mediated and humoral immune responses. Adv Contra Deliv Syst 10:267-276, 1994.
9. American Fertility Society: Revised American Fertility Society Classification of Endometriosis. Fertil Steril 43:351-356, 1985.
10. Bartosik D: Immunologic aspects of endometriosis. Semin Reprod Endocrinol 3:329-333, 1985.
11. Hill JA, Paris HP, Schiff I, et al: Characterization of leukocyte subpopulations in the peritoneal fluid of women with endometriosis. Fertil Steril 50:216-222, 1988.
12. Oosterlynck DJ, Meuleman C, Waer M, et al: The natural killer activity of peritoneal fluid lymphocytes is decreased in women with endometriosis. Fertil Steril 58:292-295, 1992.
13. Simon C, Gomez E, Mir A, et al: Glucocorticoid treatment decreases serum embryotoxicity in endometriosis patients. Fertil Steril 58:284-289, 1992.
14. Haney AF, Muscato JJ, Weinberg JB: Peritoneal fluid cell populations in infertility patients. Fertil Steril 35:696-698, 1987.
15. Syrop CH, Halme J: Cyclic changes of peritoneal fluid parameters in normal and infertile patients. Obstet Gynecol 69:416-418, 1987.
16. Hill JA: Immunology and endometriosis. Fertil Steril 58:262-264, 1992.
17. Sthoeger ZM, Chiorazz N, Lahita G: Regulation of the immune response by sex hormones. In vitro effect of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. J Immunol 141:91-95, 1981.
18. Grossman GJ: Interactions between the gonadal steroids and the immune system. Science 227: 257-261, 1985.
19. Sakata M, Terakawa N, Mizutani T, et al: Effects of danazol, gonadotropin-releasing hormone agonist and a combination of danazol and gonadotropinreleasing hormone agonist on experimental endometriosis. Am J Obstet Gynecol 1623:1679-1684, 1990.